Sign In
Buy PCVX
$51.96
-0.150 (-0.288%)
At Close: Jun 23, 2026
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Cri
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)
01:30pm, Monday, 26'th Aug 2024
NEW YORK , Aug. 26, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vaxcyte, Inc. (NASDAQ: PCVX) on behalf of the company's shareholders. The investigation seeks to d
Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
10:56am, Wednesday, 31'st Jul 2024
The consensus price target hints at a 25.2% upside potential for Vaxcyte (PCVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice
01:00pm, Monday, 29'th Jul 2024
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Vaxcyte Appoints John Furey to Board of Directors
08:30am, Tuesday, 02'nd Jul 2024
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacter
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
04:05pm, Wednesday, 08'th May 2024
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcy
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
04:05pm, Tuesday, 02'nd Apr 2024
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know
01:01pm, Wednesday, 28'th Feb 2024
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript
12:32am, Wednesday, 28'th Feb 2024
Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:01pm, Tuesday, 27'th Feb 2024
-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult Prog
Why Vaxcyte (PCVX) Might Surprise This Earnings Season
09:36am, Monday, 26'th Feb 2024
Vaxcyte (PCVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Stocks to Buy That Are Poised to Beat on Earnings This Week
08:41am, Monday, 26'th Feb 2024
We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
04:05pm, Thursday, 15'th Feb 2024
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
